PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates

Financial Performance - PTC Therapeutics reported a quarterly loss of $0.83 per share, better than the Zacks Consensus Estimate of a loss of $1.07, and an improvement from a loss of $1.16 per share a year ago, representing an earnings surprise of +22.43% [1] - The company posted revenues of $178.88 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.82%, although this is a decrease from year-ago revenues of $186.7 million [2] - Over the last four quarters, PTC Therapeutics has exceeded consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - PTC Therapeutics shares have increased approximately 13.8% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.01 on revenues of $184.3 million, while for the current fiscal year, the estimate is $7.62 on revenues of $1.74 billion [7] - The outlook for the industry, specifically the Medical - Biomedical and Genetics sector, is favorable, ranking in the top 41% of over 250 Zacks industries, suggesting potential for outperformance [8]